(MENAFN- GlobeNewsWire - Nasdaq) Dublin, Jan. 29, 2025 (GLOBE NEWSWIRE) -- The "Endoscopic Retrograde Cholangiopancreatography market Size, Share & Trends Analysis by Product, Procedure Type, End-use, and Region, 2025-2030" report has been added to ResearchAndMarkets.com's offering.
The global endoscopic retrograde cholangiopancreatography market size was estimated at USD 2.17 billion in 2024 and is anticipated to grow at a CAGR of 8.26% from 2025 to 2030. The growth of the endoscopic retrograde cholangiopancreatography (ERCP) market is primarily driven by the rising incidence of pancreatic and biliary diseases, such as gallstones, pancreatitis, and bile duct obstructions. As the population ages and lifestyles change, these conditions are becoming more prevalent, increasing the demand for ERCP procedures. A study published in Clinical Gastroenterology and Hepatology in February 2024 estimates a global gallstone prevalence of 6%, with higher rates in females and in South America. The incidence of gallstones is expected to rise sharply over the forecast period, further fueling ERCP demand.
Advancements in endoscopic technology have improved ERCP safety and efficacy. For example, in January 2023, Advantech introduced the MIO-5377R single-board computer, designed to enhance endoscopic performance, reliability, and functionality. Innovations such as high-definition imaging, improved endoscope maneuverability, and advanced therapeutic accessories have made ERCP a more precise and effective diagnostic and treatment tool, attracting both healthcare providers and patients.
The growing adoption of minimally invasive surgical techniques is also driving ERCP demand. According to the American Cancer Society's annual report (January 2024), an estimated 41,630 new liver cancer cases will be diagnosed in the U.S. Liver cancer is more prevalent in Southeast Asia and sub-Saharan Africa, where it is the most common cancer type, with over 800,000 new cases diagnosed globally each year. It is also a leading cause of cancer-related deaths, claiming over 700,000 lives annually.
The high burden of cholangiocarcinoma and hepatocellular carcinoma is expected to further boost ERCP adoption for early cancer detection. Increased awareness of the benefits of early diagnosis and treatment of pancreatic and biliary diseases has heightened demand for minimally invasive procedures. In October 2023, the Biliary Atresia Awareness Committee launched a campaign under the auspices of Gauteng Provincial Solid Organ Transplant Division and the University of the Witwatersrand at Charlotte Maxeke Academic Hospital. The initiative aimed to raise awareness and support for children with biliary atresia, a rare and life-threatening liver disease affecting infants. It focused on educating diverse populations, providing resources to affected families, advancing diagnostic research, and fostering global medical collaboration.
An aging population is another key driver of market growth. As chronic conditions such as coagulopathy and anemia become more common in older adults, the demand for ERCP and related procedures, including those requiring blood transfusions, is rising. Currently, over 40 million people in the U.S. are aged 65 or older, a number expected to double by 2050. Japan, home to the world's largest geriatric population, presents significant growth opportunities. According to the WHO, the geriatric population is projected to reach 22% globally by 2050.
Healthcare organizations are increasingly investing in research and partnerships to drive innovation. A Optica Publishing Group study (July 2022) highlighted the development of a photoacoustic imaging endoscope probe, which can be inserted into a medical needle as small as 0.6 mm in diameter. Researchers also suggested AI could accelerate imaging procedures.
Strategic initiatives by market players, including mergers, acquisitions, and product launches, are expected to further propel growth. For instance, in April 2022, Olympus partnered with EndoClot Plus, a company specializing in hemostasis technologies. EndoClot PHS, a nonthermal, nontraumatic solution for gastrointestinal bleeding, is a key product in its portfolio. This partnership aims to improve accessibility to EndoClot PHS, enabling gastroenterologists to stop bleeding quickly and effectively during procedures.
Why should you buy this report?
Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments. Competitive Landscape: Explore the market presence of key players worldwide. Future Trends: Discover the pivotal trends and drivers shaping the future of the global market. Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
Market intelligence to enable effective decision-making Market estimates and forecasts from 2018 to 2030 Growth opportunities and trend analyses Segment and regional revenue forecasts for market assessment Competition strategy and market share analysis Product innovation listing for you to stay ahead of the curve
Key Attributes
| Report Attribute | Details |
| No. of Pages | 120 |
| Forecast Period | 2024-2030 |
| Estimated Market Value (USD) in 2024 | $2.17 billion |
| Forecasted Market Value (USD) by 2030 | $3.51 billion |
| Compound Annual Growth Rate | 8.2% |
| Regions Covered | Global |
Key Topics Covered
Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Segment Definitions
1.3. Research Methodology
1.4. Information Procurement
1.5. Information or Data Analysis
1.6. Market Formulation & Validation
1.7. Model Details
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Regional Outlook
2.4. Competitive Insights
Chapter 3. Endoscopic Retrograde Cholangiopancreatography Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.3. Endoscopic Retrograde Cholangiopancreatography Market Analysis Tools
Chapter 4. Endoscopic Retrograde Cholangiopancreatography Market: Product Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Endoscopic Retrograde Cholangiopancreatography Market: Product Movement Analysis
4.3. Endoscopic Retrograde Cholangiopancreatography Market by Product Outlook (USD Million)
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
4.5. Endoscopes
4.6. Endotherapy Devices
4.7. Visualization Systems
4.8. Energy Devices
4.9. Others
Chapter 5. Endoscopic Retrograde Cholangiopancreatography Market: Procedure Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Endoscopic Retrograde Cholangiopancreatography Market: Procedure Movement Analysis
5.3. Endoscopic Retrograde Cholangiopancreatography Market by Procedure Outlook (USD Million)
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
5.5. Biliary Sphincterotomy
5.6. Biliary Stenting
5.7. Biliary Dilatation
5.8. Pancreatic Sphincterotomy
5.9. Pancreatic Duct Stenting
5.10. Pancreatic Duct Dilation
Chapter 6. Endoscopic Retrograde Cholangiopancreatography Market: End Use Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Endoscopic Retrograde Cholangiopancreatography Market: End Use Movement Analysis
6.3. Endoscopic Retrograde Cholangiopancreatography Market by End Use Outlook (USD Million)
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
6.5. Hospitals
6.6. Outpatient Facilities
Chapter 7. Endoscopic Retrograde Cholangiopancreatography Market: Regional Estimates & Trend Analysis
7.1. Regional Dashboard
7.2. Regional Endoscopic Retrograde Cholangiopancreatography Market Movement Analysis
7.3. Endoscopic Retrograde Cholangiopancreatography Market: Regional Estimates & Trend Analysis by Technology & End Use
7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
7.5. North America
7.6. Asia-Pacific
7.7. Latin America
7.8. Middle East & Africa
Chapter 8. Competitive Landscape
8.1. Market Participant Categorization
8.2. Key Company Profiles
8.2.1. Olympus Corporation
8.2.2. CONMED Corporation
8.2.3. Boston Scientific Corporation
8.2.4. Medtronic plc
8.2.5. Telemed System, Inc.
8.2.6. AMBU, Inc.
8.2.7. Fujifilm Holdings Corporation
8.2.8. Hobbs Medical, Inc.
8.2.9. Cook Group
8.2.10. Streis plc
8.2.11. HOYA Group
8.2.12. Karl Storz SE & Co. KG
For more information about this report visit
About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
Endoscopic Retrograde Cholangiopancreatography Market
CONTACT:
CONTACT:
Laura Wood,Senior Press Manager
...
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
MENAFN29012025004107003653ID1109144653
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.